These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 29344718)

  • 21. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
    Girum KB; Cottereau AS; Vercellino L; Rebaud L; Clerc J; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
    J Nucl Med; 2024 Feb; 65(2):313-319. PubMed ID: 38071535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
    Zhang YY; Song L; Zhao MX; Hu K
    Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL.
    Zhao P; Yu T; Pan Z
    Ann Nucl Med; 2021 Jan; 35(1):24-30. PubMed ID: 33001389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
    Cottereau AS; El-Galaly TC; Becker S; Broussais F; Petersen LJ; Bonnet C; Prior JO; Tilly H; Hutchings M; Casasnovas O; Meignan M
    J Nucl Med; 2018 Apr; 59(4):589-595. PubMed ID: 28864629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
    Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
    Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.
    Cottereau AS; Hapdey S; Chartier L; Modzelewski R; Casasnovas O; Itti E; Tilly H; Vera P; Meignan MA; Becker S
    J Nucl Med; 2017 Feb; 58(2):276-281. PubMed ID: 27754905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will Baseline Total Lesion Glycolysis Play a Role in Improving the Prognostic Value of the NCCN-IPI in Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated With the R-CHOP Regimen?
    Jiang C; Ding C; Xu J; Teng Y; Chen J; Wang Z; Zhou Z
    Clin Nucl Med; 2021 Jan; 46(1):1-7. PubMed ID: 33181743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Acta Radiol; 2016 Jun; 57(6):733-41. PubMed ID: 26297729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.
    Schmitz C; Hüttmann A; Müller SP; Hanoun M; Boellaard R; Brinkmann M; Jöckel KH; Dührsen U; Rekowski J
    Eur J Cancer; 2020 Jan; 124():25-36. PubMed ID: 31710995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Impact of Pretreatment 2-[
    Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
    [No Abstract]   [Full Text] [Related]  

  • 33. Prognostic significance of integrating total metabolic tumor volume and EGFR mutation status in patients with lung adenocarcinoma.
    Jiang M; Guo X; Chen P; Zhang X; Gao Q; Zhang J; Zheng J
    PeerJ; 2024; 12():e16807. PubMed ID: 38250731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of baseline total metabolic tumour volume of
    Gong H; Li T; Li J; Tang L; Ding C
    EJNMMI Res; 2021 Jul; 11(1):64. PubMed ID: 34264417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of the methodological aspects of the dichotomization of total metabolic tumor volume measured through baseline fluorine-18 fluorodeoxyglucose PET on survival prediction in lymphoma.
    Lue KH; Chen YH; Wu YF; Liu SH
    Nucl Med Commun; 2023 Jan; 44(1):74-80. PubMed ID: 36514929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.
    Le Goff E; Blanc-Durand P; Roulin L; Lafont C; Loyaux R; MBoumbae DL; Benmaad I; Claudel A; Poullot E; Robe C; Gricourt G; Aissat A; Copie-Bergman C; Lemonnier F; Gaulard P; Itti E; Haioun C; Delfau-Larue MH
    Br J Haematol; 2023 Jul; 202(1):54-64. PubMed ID: 37038217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Significance Of Sequential 18f-fdg Pet/Ct During Frontline Treatment Of Peripheral T Cell Lymphomas.
    Song GY; Jung SH; Ahn SY; Kim M; Ahn JS; Lee JJ; Kim HJ; Moon JB; Yoo SW; Kwon SY; Min JJ; Bom HS; Kang SR; Yang DH
    Korean J Intern Med; 2024 Mar; 39(2):327-337. PubMed ID: 38268194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.
    Blanc-Durand P; Jégou S; Kanoun S; Berriolo-Riedinger A; Bodet-Milin C; Kraeber-Bodéré F; Carlier T; Le Gouill S; Casasnovas RO; Meignan M; Itti E
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1362-1370. PubMed ID: 33097974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients.
    Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
    Med Oncol; 2017 Feb; 34(2):29. PubMed ID: 28083854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.
    Cottereau AS; Versari A; Loft A; Casasnovas O; Bellei M; Ricci R; Bardet S; Castagnoli A; Brice P; Raemaekers J; Deau B; Fortpied C; Raveloarivahy T; Van Zele E; Chartier L; Vander Borght T; Federico M; Hutchings M; Ricardi U; Andre M; Meignan M
    Blood; 2018 Mar; 131(13):1456-1463. PubMed ID: 29437590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.